Stoke Therapeutics Inc. (STOK)
8.65
-0.27 (-3.03%)
At close: Jan 14, 2025, 3:59 PM
8.68
0.35%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 7 |
| Market Cap | 458.16M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.08 |
| PE Ratio (ttm) | -4.16 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 9.74 |
| Volume | 670,354 |
| Avg. Volume (20D) | 624,552 |
| Open | 9.00 |
| Previous Close | 8.92 |
| Day's Range | 8.42 - 9.13 |
| 52-Week Range | 4.09 - 17.58 |
| Beta | undefined |
About STOK
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome,...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 19, 2019
Employees 110
Stock Exchange NASDAQ
Ticker Symbol STOK
Analyst Forecast
According to 8 analyst ratings, the average rating for STOK stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 131.21% from the latest price.
Buy 87.50%
Hold 12.50%
Sell 0.00%
Next Earnings Release
Stoke Therapeutics Inc. is scheduled to release its earnings on Mar 24, 2025,
during market hours.
Analysts project revenue of $2.97M, reflecting a 6.03% YoY growth and earnings per share of -0.56, making a -6.67% decrease YoY.
Analysts project revenue of $2.97M, reflecting a 6.03% YoY growth and earnings per share of -0.56, making a -6.67% decrease YoY.
1 month ago ·
Source
+12.07%
Stoke Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
2 months ago ·
Source
+1.53%
Stoke Therapeutics shares are trading higher on possible continued strength following Q3 reported financial results yesterday. Also, Needham and HC Wainwright & Co. reiterated Buy ratings on the stock.
